PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

Budget Impact ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Menopausal Women ◽

Epidermal Growth ◽

Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1067 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1067-1067

Author(s):

Nicole Princic ◽

Derek Tang ◽

Aditya Bardia ◽

David Smith ◽

William M. Johnson ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Real World Setting ◽

Menopausal Women ◽

Epidermal Growth ◽

Abstract P1-18-18: PIK3CA mutation testing prevalence among post-menopausal (PM) women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) using real world data

10.1158/1538-7445.sabcs19-p1-18-18 ◽

2020 ◽

Author(s):

Nicole Princic ◽

Qayyim Said ◽

David Smith ◽

William Johnson ◽

Ayal Aizer

Keyword(s):

Breast Cancer ◽

Pik3ca Mutation ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Real World Data ◽

Epidermal Growth ◽

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Current Medical Research and Opinion ◽

10.1185/03007995.2015.1062358 ◽

2015 ◽

Vol 31 (8) ◽

pp. 1573-1582 ◽

Cited By ~ 3

Author(s):

Nanxin Li ◽

Yanni Hao ◽

Jipan Xie ◽

Peggy L. Lin ◽

Zhou Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Associated Factors ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Menopausal Women ◽

Epidermal Growth ◽

Abstract P1-13-06: Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)

10.1158/1538-7445.sabcs14-p1-13-06 ◽

2015 ◽

Author(s):

James Signorovitch ◽

Jenny Wang ◽

Ruo-Ding Tan ◽

Darren Thomason ◽

Andrew Kageleiry ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Visceral Metastases ◽

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-09-01 ◽

2018 ◽

Cited By ~ 4

Author(s):

HS Rugo ◽

P Kabos ◽

MN Dickler ◽

WJ John ◽

I Smith ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 1B ◽

Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective

Value in Health ◽

10.1016/j.jval.2017.08.202 ◽

2017 ◽

Vol 20 (9) ◽

pp. A433 ◽

Cited By ~ 1

Author(s):

R Hettle ◽

G Suri ◽

R Mistry ◽

D Chandiwana ◽

A Lee

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Epidermal Growth ◽

Uk National Health Service ◽

Service Perspective

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

10.1158/1538-7445.am2020-ct108 ◽

2020 ◽

Author(s):

Hope S. Rugo ◽

J. Thad Beck ◽

Guy Jerusalem ◽

Hans Wildiers ◽

Peter Kabos ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 1B ◽

Abemaciclib▼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Cancer Nursing Practice ◽

10.7748/cnp.2020.e1658 ◽

2020 ◽

Author(s):

Pauline Mcllroy

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Advances in Therapy ◽

10.1007/s12325-020-01552-2 ◽

2020 ◽

Author(s):

Gayathri Nagaraj ◽

Cynthia X. Ma

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Literature Review ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1479246 ◽

2018 ◽

Vol 34 (9) ◽

pp. 1645-1652 ◽

Cited By ~ 4

Author(s):

Rajeev Ayyagari ◽

Derek Tang ◽

Oscar Patterson-Lomba ◽

Zhou Zhou ◽

Jipan Xie ◽

...

Keyword(s):

Breast Cancer ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Progression Free Survival ◽

Free Survival ◽